15 - Drug-Eluting Bead Transarterial Chemoembolization Treatment of Liver-Dominant Metastatic Leiomyosarcoma

Sunday, April 12, 2026

3:18 PM - 3:27 PM ET

Presenting Author(s)

JH

Jonathan Henning, BS

Medical Student
University of South Florida Morsani College of Medicine, United States

Author/Co-author(s)

SV

Shree Venkat, MD

Assistant Member in Diagnostic Imaging and Interventional Radiology
H. Lee Moffitt Cancer Center, United States
Premsai Charan Kumar, MD

PGY-2 , Interventional Radiology Resident
USF Morsani College of Medicine, United States
Ghassan El-Haddad, MD

Senior Member Interventional Radiology, Medical Director Radionuclide Therapy Program
Moffitt Cancer Center and Research Institute, United States
AB

Andrew Brohl, MD

Medical Oncologist
Moffitt Cancer Center, United States
MR

Mauricio Ribeiro, MD

Medical Oncologist
University of South Florida Morsani College of Medicine, United States
MD

Mihaela Druta, MD

Medical Oncologist
Moffitt Cancer Center, United States
RM

Rahul Mhaskar, n/a

medical student
USF Health Morsani College of Medicine, United States
AN

Arash Naghavi, MD

Associate Professor of Radiation Oncology
Moffitt Cancer Center, United States
Bela Kis, MD, PhD, FSIR (he/him/his)

Section Chief
Moffitt Cancer Center, United States

Purpose: To analyze the safety and efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) for unresectable metastatic hepatic leiomyosarcoma.

Materials and Methods: Medical records of patients with metastatic hepatic leiomyosarcoma who underwent doxorubicin DEB-TACE from December 2014 to September 2024 were retrospectively reviewed to evaluate radiographic response, survival and clinical and biochemical toxicities. The study included 29 patients (9 males, 20 females; average age 60.1 ± 12.7 years). 23 patients (79.3%) had bilobar and 6 patients (20.7%) had unilobar disease. 20 patients (69%) had extrahepatic metastases at the time of the first DEB-TACE. 25 patients (86%) received multiple lines of systemic therapies before DEB-TACE. The median number of systemic therapies prior to TACE was 3 (range: 1-6 lines) and 48% of patients had high grade histology.

Results: The median overall survival from the first DEB-TACE was 16.3 months (95% CI 2.2; 30.4), from diagnosis of liver metastasis was 35.8 months (95% CI 21.0; 50.6), and from primary diagnosis was 67.5 months (95% CI 49.2; 85.8). At 3 months post-DEB-TACE, the objective response was 79% (23 out of 29 patients), and the disease control rate was 96% (28 out of 29 patients), evaluated by mRECIST. The median liver progression-free survival from the first DEB-TACE was 7.8 months (95% CI 4.5; 11.2). The 1-, 2-, and 3-year survival rates from the diagnosis of liver metastasis were 93%, 69% and 38% respectively. There were two grade 3 clinical toxicities, four grade 3 laboratory toxicities, and 20 grade 1 or 2 laboratory toxicities. There was no 30-day mortality and no mortality related to DEB-TACE.

Conclusion: DEB-TACE was safe and effective treatment in a group of heavily pretreated, chemotherapy-refractory patients with liver-dominant unresectable leiomyosarcoma. DEB-TACE showed promising hepatic disease control and survival benefit with minimal side effects. This study is the largest reported cohort of patients with metastatic leiomyosarcoma treated with DEB-TACE. The results of this study can serve as the basis for prospective multi-institutional study to prove the benefits of DEB-TACE in chemotherapy-refractory metastatic leiomyosarcoma.